NS-2359

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
NS-2359
NStwothreefivenine.png
Systematic (IUPAC) name
(1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-azabicyclo[3.2.1]octane
Identifiers
ATC code none
PubChem CID: 11408320
Chemical data
Formula C15H19Cl2NO
Molecular mass 300.223 g/mol
  • Clc1ccc(cc1Cl)C(C2COC)CC3NC2CC3
  (verify)

NS-2359 (GSK-372,475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant,[1] but was discontinued in 2009 when phase II clinical trials turned up disappointing results and did not support further effort by the company.[1] NS-2359 was also in clinical trials for the treatment of ADHD,[2] phase II having been completed in 2007.[3] A trial exploring the effect of NS-2359 on cocaine-experienced individuals is currently ongoing.[4]

Another scientific article on NS-2359 was recently (2011) published.[5] As can be seen from reading the abstract to the citation, the compound failed to perform in clinical trials for the treatment of depression.

See also

References

  1. ↑ 1.0 1.1 Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ http://clinicaltrials.gov/ct2/show/NCT00467428
  4. ↑ http://clinicaltrials.gov/ct2/show/NCT00032916
  5. ↑ Lua error in package.lua at line 80: module 'strict' not found.


<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=NS-2359&oldid=678209455"